Shingles vaccine shortage leaving these adults vulnerable to painful disease

CDC has reported a nationwide shortage of the new shingles vaccine, zoster vaccine recombinant, adjuvanted (Shingrix—GlaxoSmithKline). GSK says it may not have enough supplies for everybody who wants it until next year.

CDC has reported a nationwide shortage of the new shingles vaccine, zoster vaccine recombinant, adjuvanted (Shingrix—GlaxoSmithKline). GSK says it may not have enough supplies for everybody who wants it until next year. Shingrix "has been met with an unprecedented level of demand from patients and health care professionals," said Sean Clements, a spokesman for the pharmaceutical company. However, the company is escalating production and says patients should continue contacting their providers to see if they have it in stock. "We understand that this is a challenging situation to manage, and GSK is fully committed to expediting Shingrix resupply throughout 2018," Clements said. "We are shipping large volumes of Shingrix every 2–3 weeks and expect that schedule to continue for the remainder of the year." Clements said consumers can use the company's online "Vaccine Locator" tool to find pharmacies that may have it, but he recommended that they still call ahead.